DNASE1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16160290	0.46	3/20
SCHEMBL6656091	0.73	2/20
SCHEMBL18670498	0.63	2/20
SCHEMBL18670563	0.59	2/20
SCHEMBL24262310	0.59	2/20
SCHEMBL18670385	0.59	2/20
SCHEMBL22341565	0.59	2/20
SCHEMBL18688343	0.58	2/20
SCHEMBL22341562	0.56	2/20
SCHEMBL13174730	0.53	2/20
SCHEMBL18670392	0.53	2/20
SCHEMBL22027680	0.51	2/20
SCHEMBL4400471	0.50	2/20
SCHEMBL13211359	0.48	2/20
SCHEMBL5957248	0.48	2/20
SCHEMBL28763780	0.48	2/20
SCHEMBL6666990	0.47	2/20
SCHEMBL9605521	0.47	2/20
SCHEMBL9923035	0.47	2/20
SCHEMBL13174903	0.46	2/20

Clinical trials — most relevant to DNASE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)	PHASE3	COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19	PHASE3	COMPLETED
Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.	PHASE2	RECRUITING
Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)	PHASE2	COMPLETED
Dornase Alpha for the Treatment of COVID-19	PHASE2	UNKNOWN
Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19	PHASE2	COMPLETED
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®	PHASE2	UNKNOWN
Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)	PHASE1	COMPLETED
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS	PHASE1	UNKNOWN
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy	PHASE1	WITHDRAWN
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant	nan	COMPLETED
Comparison of ICSI Outcomes in Cycles Using Testicular and Ejaculate Sperm From Couples With High SDF	nan	COMPLETED
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)	nan	RECRUITING
Characterization of Sperm Population Following Different Selection Procedures	nan	UNKNOWN
Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)	nan	ENROLLING_BY_INVITATION
Pancreatic Injury and Corresponding Management Outcome (PICO)	nan	UNKNOWN
Predicting Pancreatic Necrosis Using mitDNA	nan	UNKNOWN
PCD New Gene Discovery	nan	COMPLETED
TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus	nan	RECRUITING
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab	nan	COMPLETED
Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus	nan	UNKNOWN
Impact of Different Cardioplegia Solutions on Indicators of Myocardial Injury During Coronary Surgery	nan	NOT_YET_RECRUITING
Covid-19: Possible Role of Neutrophil Extracellular Traps	nan	UNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups	nan	UNKNOWN
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DNASE1 binder may also engage these)

Protein	Name	Similarity
Q4AEE3	—	0.999	Q4AEE3 →
Q767J3	—	0.996	Q767J3 →
P21704	—	0.995	P21704 →
P11936	—	0.994	P11936 →
P49183	—	0.993	P49183 →
P00639	—	0.989	P00639 →
O18998	—	0.989	O18998 →
Q9D1G0	—	0.987	Q9D1G0 →
P11937	—	0.986	P11937 →
Q92874	—	0.983	Q92874 →
Q9YGI5	—	0.976	Q9YGI5 →
O42446	—	0.967	O42446 →
P49184	—	0.966	P49184 →
Q2QDE6	—	0.962	Q2QDE6 →
Q2QDF0	—	0.960	Q2QDF0 →
Q2QDF1	—	0.960	Q2QDF1 →
Q92485	—	0.959	Q92485 →
Q2QDE9	—	0.959	Q2QDE9 →
O55070	—	0.955	O55070 →
Q9D7J6	—	0.954	Q9D7J6 →
P58242	—	0.952	P58242 →
O89107	—	0.952	O89107 →
Q2QDE7	—	0.950	Q2QDE7 →
ALG1	Chitobiosyldiphosphodolichol beta-mannosyltransferase	0.950	landscape →
O89023	—	0.949	O89023 →
Q5R7A2	—	0.948	Q5R7A2 →
Q5R9N3	—	0.948	Q5R9N3 →
Q8WMP9	—	0.948	Q8WMP9 →
DNASE1L3	Deoxyribonuclease gamma	0.947	landscape →
O46432	—	0.947	O46432 →